Arkolith/Insider Trading/ZVSA/Form 4

Glover Stephen C.

Chief Executive Officer, DirectorZyVersa Therapeutics, Inc. (ZVSA) · full profile →Form 4 · filed Dec 14, 2022
No Open-Market Flow
Open-Market Buys
$0
Open-Market Sells
$0
Net Open-Market Flow
$0
Transactions
14
4 non-derivative · 10 derivative

Non-Derivative Transactions (Table I)

DateActionSharesPriceValueOwned After
Dec 12, 2022Grant(A)50K——50K
Dec 12, 2022Grant(A)85K——85K
Dec 12, 2022Grant(A)449K——449K
Dec 12, 2022Grant(A)44K——44K

Derivative Transactions (Table II)

DateActionSharesPriceValueOwned After
Dec 12, 2022Grant(A)79K—$079K
Dec 12, 2022Grant(A)71K—$071K
Dec 12, 2022Grant(A)3K—$03K
Dec 12, 2022Grant(A)18K—$018K
Dec 12, 2022Grant(A)126K—$0126K
Dec 12, 2022Grant(A)265K—$0265K
Dec 12, 2022Grant(A)2K——2K
Dec 12, 2022Grant(A)139K—$0139K
Dec 12, 2022Grant(A)18——2K
Dec 12, 2022Grant(A)169K—$0169K

Transaction Codes

A
Grant / award

Data Source & Provenance

Parsed from a single SEC EDGAR Form 4 filing (accession 0001493152-22-035479) within minutes of acceptance. Every field above traces to the original document. Verify it directly:

View original filing on SEC.govRaw Form 4 XML